# 510(k) SUMMARY

(As required by 21.CFR.807.92)

# Introduction:

According to the requirements of 21 CFR.807.92, the following information provides sufficient data to understand the basis for a determination of substantial equivalence.

# Submitted By:

US Diagnostics, Inc. 304 Park Avenue South Suite 218 New York, NY 10010

# Contact Person:

Edward Letko Phone: 917-402-5900 Fax: 212-202-5173

# Date Summary, Prepared:

March 07, 2006

# Device Name:

Propriety Name: G4TM Common Name: Blood Glucose Test System Classification Name: Class II, 862.1345 Glucose Blood Tester

# Predicate Device:

We claim substantial equivalence to the LifeScan, Inc., OneTouch $^ { \textregistered }$ Ultra $^ \mathrm { \textregistered }$ .

# Device Description:

The $\mathrm { G 4 ^ { r m } }$ Monitor is an in vitro diagnostic device designed for measuring the concentration of glucose in capillary whole blood, which is used with the $\mathbf { G 4 7 M }$ Test Strips.

The test principle is:

This device is an in vitro diagnostic product intended for the measurement of glucose concentration in human blood. The principle of the test relies upon a specific type of glucose in the blood sample, the dehydrogenase glucose that reacts to electrodes in the test strip. The test strip employs an electrochemical signal generating an electrical current that will stimulate a chemical reaction.This reaction is measured by the Meter and displayed as your blood glucose result.

# Intended Use:

The $\mathbf { G 4 7 M }$ Diabetes Monitoring System is used for the quantitative measurement of glucose level in capillary whole blood as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings. $\mathrm { G } 4 ^ { \mathrm { T M } }$ System is for

# 510(k) Summary, Continued

testing outside the body (in vitro diagnostic use only). Testing sites include the traditional fingertip testing along with alternate site testing on the forearm giving it an attractive, nearly painless alternative to the more painful fingertip site. The $\mathrm { G } 4 ^ { \mathrm { T M } }$ Control Solutions are a red liquid which is to be used to check that both the $\mathrm { G } 4 ^ { \mathrm { { T M } } }$ meter and $\mathrm { G } 4 ^ { \mathrm { { T M } } }$ test strips are working together properly. It contains a known range of glucose as specified on the vial.

# Comparison to Predicate Device:

The US Diagnostics, Inc. $\mathbf { G } 4 ^ { \mathbf { T M } }$ Module is substantially equivalent to the other products in commercial distribution intended for similar use. The most notable, it is substantially equivalent to the currently marketed item, the OneTouch $^ \mathrm { \textregistered }$ Ultra $^ { \textregistered }$ by LifeScan, Inc.

# Conclusion:

The G4TM Blood Glucose Monitoring System is substantially equivalent to the following predicate devices: K024194 LifeScan, Inc. OneTouch $^ { \textregistered }$ Ultra $^ { \textregistered }$ K984261 - LifeScan, Inc. SURESTEP $^ \mathrm { \textregistered }$ K021513  Roche Diagnostics Corp. Accu-Chek Advantage

Mr. Edward Letko Managing Director US Diagnostics, Inc. 304 Park Avenue South Suite 218 New York, NY 10010

# APR 1 4 2006

Rc: k051651 Trade/Device Name: $\mathrm { G 4 ^ { r \mathbf { M } } }$ Meter, G4TM Test Strips, $\mathrm { G 4 ^ { r \mathrm { n } } }$ Control Solutions Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ EPY Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, CGA, JJX Dated: March 10, 2006 Received: March10, 2006

Dear Mr. Letko

We have reviewed your Section 51o(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the cnactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (sec above) into cither class I1 (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR). Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial cquivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including but not limited to: registration and listing (21 (FR Part S07); labeling (21 CFR Parts 801 and s09): and good manufacturing practice requirenents as set forth in the quality systems (QS) regulation (21 (FR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/634ee6d2eef323d4f02a6cb326597ca0c19d5533fd318e11ceec0520e1ecde19.jpg)

Alberto Gutierrez, Ph.D. Â¸   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number: K051651

# Device Name: G4TM

Indications For Use: The G4Tm Meter device is used for the quantitative measurement of glucose level in capillary whole blood as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings. G4rm System is for testing outside the body (in vitro diagnostic use only). Testing sites include the traditional fingertip testing along with alternate site testing on the arm.

The $\mathrm { G } 4 ^ { \mathrm { { r m } } }$ Test Strips is used for the quantitative measurement of glucose level in capillary whole blood as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings. G4Tm System is for testing outside the body (in vitro diagnostic use only). Testing sites include the traditional fingertip testing along with alternate site testing on the arm.

The G4Tm Control Solutions are a red liquid which is to be used to check that both the G4TM meter and G4TM test strips are working together properly. It contains a known range of glucose as specified on the vial.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concyrrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Tiee of In Vitro Diagnostic Devi byation and Cafoty

Confidential US Diagnostics, Ine.